Montgomery based law firm Beasley, Allen, Crow, Methvin, Portis & Miles, P.C., has named four attorneys as new Principals: David Dearing, James Lampkin, Danielle Ward Mason, and Matt Teague. All four lawyers work in the firm’s Mass Torts Section.
“We appreciate the work these talented attorneys have done for their clients on behalf of the firm, and anticipate their continued success in fulfilling our mission of ‘helping those who need it most,’” said Beasley Allen Principal & Managing Attorney Tom Methvin.
David Dearing joined Beasley Allen in 2012. He initially worked on our Hormone Replacement Therapy (HRT) litigation team, focusing on drugs such as Premarin, Prempro and Provera, which were shown to cause breast cancer in some women. Mr. Dearing is now primarily working on two other classes of drugs in multidistrict litigation: Fosamax, used to treat osteoporosis but linked to femur fracture; and diabetes drugs Januvia, Byetta, Janumet and Victoza, linked to the development of pancreatic cancer.
James W. Lampkin, II, joined Beasley Allen in 2011 after a career in private practice with a civil defense firm in Mobile. At Beasley Allen, James is handling cases related to the medical device transvaginal mesh (TVM), which is used to repair conditions such as pelvic organ prolapse and stress urinary incontinence. The mesh can erode into the body’s tissue, migrate and perforate organs, causing serious chronic pain. James also is working on cases involving Risperdal, a drug used to treat schizophrenia, bipolar disorder and irritability with autism. The drug has been linked to the development of gynocomastia, a condition in which boys grow breast tissue.
Danielle Ward Mason joined Beasley Allen in 2009. She is currently handling cases involving the drug Reglan, which is used to treat gastric problems but has been linked to the development of uncontrolled muscle movements, a condition known as Tardive Dyskinesia. She also is working on claims related to transvaginal mesh (TVM). Danielle also was part of the trial team that worked on Hormone Replacement Therapy (HRT) litigation and secured a $72.6 million verdict on behalf of three plaintiffs in Philadelphia who took HRT drugs and later developed breast cancer.
Matthew P. Teague joined Beasley Allen in 2011. He is leading the firm’s Testosterone Replacement Therapy litigation, representing men who suffered significant injuries such as heart attack, stroke, blood clots and related conditions, or who died, after using testosterone replacement drugs. These drugs, heavily marketed to treat a condition dubbed “Low T,” include AndroGel, Testim and Axiron, among others. Matt also is involved in the firm’s transvaginal mesh (TVM) litigation.
Additionally, Beasley Allen has named seven new Associates. They are Jenna Day (Toxic Torts Section), Stephanie Monplaisir (Personal Injury / Products Liability Section), Leslie Pescia (Fraud Section), Rebecca Gilliland (Fraud Section), Beau Darley (Mass Torts Section), Liz Eiland (Mass Torts Section) and Matt Munson (Mass Torts).